

AMENDMENT TO COMMITTEE PRINT
OFFERED BY MR. TIM MURPHY
(PED-EXCLUSIV__002, June 11, 2007)

Page 16, after line 9, insert the following new subparagraph:

1 “(D) RELATIONSHIP TO ORPHAN DRUG
2 ACT.—Notwithstanding subparagraph (A), in
3 the case of a drug designated under section 526
4 for a rare disease or condition, this paragraph
5 does not authorize the Secretary to reduce any
6 additional period of market exclusivity under
7 section 527(a) that otherwise would apply
8 under subsection (b) or (c) of this section.